Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment

Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In additi...

Full description

Bibliographic Details
Main Authors: Luis Sarabia De Ardanaz, Jose M. Andreu-Ubero, Miriam Navidad-Fuentes, Miguel Ángel Ferrer-González, Victor Ruíz del Valle, Inmaculada Salcedo-Bellido, Rocío Barrios-Rodríguez, Rafael Cáliz-Cáliz, Pilar Requena
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.620187/full
id doaj-7e8e43bdcb734477aeaad284246cb0b8
record_format Article
spelling doaj-7e8e43bdcb734477aeaad284246cb0b82021-07-01T15:02:32ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-07-011210.3389/fphar.2021.620187620187Tocilizumab in COVID-19: Factors Associated With Mortality Before and After TreatmentLuis Sarabia De Ardanaz0Jose M. Andreu-Ubero1Miriam Navidad-Fuentes2Miguel Ángel Ferrer-González3Victor Ruíz del Valle4Inmaculada Salcedo-Bellido5Inmaculada Salcedo-Bellido6Inmaculada Salcedo-Bellido7Rocío Barrios-Rodríguez8Rocío Barrios-Rodríguez9Rocío Barrios-Rodríguez10Rafael Cáliz-Cáliz11Pilar Requena12Departamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, EspañaInstituto de Investigación Biosanitaria (ibs.Granada), Granada, SpainConsortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, SpainDepartamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, EspañaInstituto de Investigación Biosanitaria (ibs.Granada), Granada, SpainConsortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, SpainDepartamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainTocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In addition, the mean differences between discharged and deceased patients in laboratory parameters measured before and 3, 6 and 9 days after TCZ administration were estimated with weighted generalized estimation equations. The variables associated with time to death were immunosuppression (Hazard Ratio-HR 3.15; 95% confidence interval-CI 1.17, 8.51), diabetes mellitus (HR 2.63; 95% CI 1.23–5.64), age (HR 1.05; 95% CI 1.02–1.09), days since diagnosis until TCZ administration (HR 1.05, 95% CI 1.00–1.09), and platelets (HR 0.27; 95% CI: 0.11, 0.69). In the post-TCZ analysis and compared to discharged patients, deceased patients had more lactate dehydrogenase (p = 0.013), troponin I (p = 0.013), C-reactive protein (p = 0.013), neutrophils (p = 0.024), and fewer platelets (p = 0.013) and lymphocytes (p = 0.013) as well as a lower average PaO2/FiO2 ratio. In conclusion, in COVID-19 diagnosed patients receiving TCZ, early treatment decreased the risk of death, while age, some comorbidities and baseline lower platelet counts increased that risk. After TCZ administration, lower platelet levels were again associated with mortality, together with other laboratory parameters.https://www.frontiersin.org/articles/10.3389/fphar.2021.620187/fullCOVID-19immunosupressiontocilizumabmortalityrisk factorplatelet
collection DOAJ
language English
format Article
sources DOAJ
author Luis Sarabia De Ardanaz
Jose M. Andreu-Ubero
Miriam Navidad-Fuentes
Miguel Ángel Ferrer-González
Victor Ruíz del Valle
Inmaculada Salcedo-Bellido
Inmaculada Salcedo-Bellido
Inmaculada Salcedo-Bellido
Rocío Barrios-Rodríguez
Rocío Barrios-Rodríguez
Rocío Barrios-Rodríguez
Rafael Cáliz-Cáliz
Pilar Requena
spellingShingle Luis Sarabia De Ardanaz
Jose M. Andreu-Ubero
Miriam Navidad-Fuentes
Miguel Ángel Ferrer-González
Victor Ruíz del Valle
Inmaculada Salcedo-Bellido
Inmaculada Salcedo-Bellido
Inmaculada Salcedo-Bellido
Rocío Barrios-Rodríguez
Rocío Barrios-Rodríguez
Rocío Barrios-Rodríguez
Rafael Cáliz-Cáliz
Pilar Requena
Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment
Frontiers in Pharmacology
COVID-19
immunosupression
tocilizumab
mortality
risk factor
platelet
author_facet Luis Sarabia De Ardanaz
Jose M. Andreu-Ubero
Miriam Navidad-Fuentes
Miguel Ángel Ferrer-González
Victor Ruíz del Valle
Inmaculada Salcedo-Bellido
Inmaculada Salcedo-Bellido
Inmaculada Salcedo-Bellido
Rocío Barrios-Rodríguez
Rocío Barrios-Rodríguez
Rocío Barrios-Rodríguez
Rafael Cáliz-Cáliz
Pilar Requena
author_sort Luis Sarabia De Ardanaz
title Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment
title_short Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment
title_full Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment
title_fullStr Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment
title_full_unstemmed Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment
title_sort tocilizumab in covid-19: factors associated with mortality before and after treatment
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2021-07-01
description Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In addition, the mean differences between discharged and deceased patients in laboratory parameters measured before and 3, 6 and 9 days after TCZ administration were estimated with weighted generalized estimation equations. The variables associated with time to death were immunosuppression (Hazard Ratio-HR 3.15; 95% confidence interval-CI 1.17, 8.51), diabetes mellitus (HR 2.63; 95% CI 1.23–5.64), age (HR 1.05; 95% CI 1.02–1.09), days since diagnosis until TCZ administration (HR 1.05, 95% CI 1.00–1.09), and platelets (HR 0.27; 95% CI: 0.11, 0.69). In the post-TCZ analysis and compared to discharged patients, deceased patients had more lactate dehydrogenase (p = 0.013), troponin I (p = 0.013), C-reactive protein (p = 0.013), neutrophils (p = 0.024), and fewer platelets (p = 0.013) and lymphocytes (p = 0.013) as well as a lower average PaO2/FiO2 ratio. In conclusion, in COVID-19 diagnosed patients receiving TCZ, early treatment decreased the risk of death, while age, some comorbidities and baseline lower platelet counts increased that risk. After TCZ administration, lower platelet levels were again associated with mortality, together with other laboratory parameters.
topic COVID-19
immunosupression
tocilizumab
mortality
risk factor
platelet
url https://www.frontiersin.org/articles/10.3389/fphar.2021.620187/full
work_keys_str_mv AT luissarabiadeardanaz tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
AT josemandreuubero tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
AT miriamnavidadfuentes tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
AT miguelangelferrergonzalez tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
AT victorruizdelvalle tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
AT inmaculadasalcedobellido tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
AT inmaculadasalcedobellido tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
AT inmaculadasalcedobellido tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
AT rociobarriosrodriguez tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
AT rociobarriosrodriguez tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
AT rociobarriosrodriguez tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
AT rafaelcalizcaliz tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
AT pilarrequena tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment
_version_ 1721346944333250560